BioCentury | Apr 22, 2017
Product Development

Playing JAKs

A desire to improve upon marketed autoimmune drug Xeljanz tofacitinib, coupled with interesting biological findings, led Pfizer Inc. to develop a portfolio of selective Janus kinase inhibitors that are taking the target into new disease...
BC Week In Review | Jan 7, 2013
Company News

Philogen, Pfizer deal

Philogen granted Pfizer exclusive, worldwide rights to develop and commercialize Dekavil , an immunocytokine consisting of a vascular targeting antibody fused to the anti-inflammatory cytokine IL-10. The product is in Phase I testing for rheumatoid arthritis...
BC Extra | Jan 4, 2013
Company News

Pfizer in deal for Philogen's Dekavil

Philogen S.p.A (Siena, Italy) granted Pfizer Inc. (NYSE:PFE) a worldwide license to Philogen's Dekavil , an immunocytokine consisting of a vascular targeting antibody fused to the anti-inflammatory cytokine IL-10. The product is in Phase I testing...
Items per page:
1 - 3 of 3